News
New FDA lung cancer OK for Celgene's Abraxane should boost sales
www.fiercepharma.com
[FiercePharma] - A much bigger payout, though, could depend on a late-stage study of pancreatic cancer. Success in this indication is seen by some analysts, including TheStreet's Adam Feuerstein, as a potential winner for investors hanging on to the Celgene CVR.
Google News: Amarin (AMRN) Ticks Lower as NCE Status Called into Question by Noted ...
[StreetInsider.com (subscription)] - Amarin Corp Plc (NASDAQ: AMRN) shares are volatile as biotech investor Adam Feuerstein is holding a live Q&A session today. Currently, the topic is Amarin. Feuerstein now thinks NCE is not going to happen for the pharma. He thinks the extended delay in
Adam Feuerstein | The Independent
www.independent.co.uk
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories. The surprise exit of Puma's regulatory chief is sparking fears FDA ...
NW Bio Refutes False Claims By Adam Feuerstein (Northwest...
article.wn.com
Feuerstein BETHESDA, Md., March 12, Northwest ...
sorted by relevance / date